HB 1064 would amend the Controlled Substances Act to add fentanyl-related substances to Schedule I. It creates a broad, multi-faceted definition of fentanyl-related substances that encompasses structural relationships to fentanyl through specified modifications and includes salts, isomers, and their salts where possible.
The bill then provides penalties by treating fentanyl-related substances as an analogue of a listed controlled substance under 21 U.S.C. 841(b)(1) and 21 U.S.C. 960(b) without requiring proof of analogue status, and it sets the effective date one day after enactment.
At a Glance
What It Does
Adds fentanyl-related substances to Schedule I via a new subsection (e) to Section 202(c) of the CSA, with a defined structural-relationship framework. It includes salts and isomers within the designation and broadens coverage beyond a single compound.
Who It Affects
Chemical suppliers, manufacturers, distributors, importers, and researchers that handle fentanyl-related substances; enforcement agencies (e.g., DEA) and prosecutors will apply the new scheduling and associated penalties.
Why It Matters
This creates a near-immediate, uniform control across a broad class of fentanyl-related substances, reducing loopholes and clarifying prosecutorial and regulatory expectations for enforcement and public safety.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill acknowledges fentanyl-related substances as a class of controlled substances by inserting a new, expansive definition into the CSA. Section 2 sets forth a schedule-placement mechanism, capturing substances that are structurally related to fentanyl through a series of specific modifications and by including salts, isomers, and salts of isomers when feasible within a given chemical designation.
This ensures that evolving analogues remain under Schedule I control, closing gaps where minor chemical variations could previously evade scheduling. Section 3 then links these substances to existing penalties by treating any fentanyl-related substance as an analogue of a named controlled substance for purposes of criminal liability, without the need to prove analogue status.
Section 4 establishes that the act takes effect one day after enactment, ensuring a prompt shift in enforcement posture. Taken together, the measure tightens the regulatory and prosecutorial framework around fentanyl-related substances and aims to deter manufacture, distribution, and possession by elevating risk and consequence while maintaining a clear legal standard.
The Five Things You Need to Know
Section 2 adds fentanyl-related substances to Schedule I under a newly added subsection (e) to CSA Section 202(c).
Fentanyl-related substances are defined by five modification pathways to capture structural relationships with fentanyl.
The definition includes salts, isomers, and salts of isomers wherever feasible within the chemical designation.
Penalties treat fentanyl-related substances as analogues under 21 U.S.C. 841(b)(1) and 21 U.S.C. 960(b) without proving analogue status.
The effective date is one day after enactment, ensuring rapid implementation.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
This section provides the act’s formal citation as the Stopping Overdoses of Fentanyl Analogues Act. It serves as the naming convention for reference in future enforcement and legislative actions.
Fentanyl-related substance scheduling
Section 2 amends Section 202(c) of the Controlled Substances Act by adding a new subsection (e). It states that any material containing fentanyl-related substances, or their salts, isomers, and salts of isomers, is included in Schedule I when such salts or isomers could exist within the designated chemical. It defines fentanyl-related substances along five modification pathways, ensuring broad coverage that captures substances structurally related to fentanyl through specific changes to the phenyl portion, phenethyl group, piperidine ring, aniline ring, and N-propionyl group. This clause is designed to close loopholes created by new synthetic derivatives.
Penalties
Section 3 establishes that a fentanyl-related substance shall be treated as an analogue of the named compound under section 401(b)(1) of the Act and section 1010(b) of the import/export provisions, without requiring proof of analogue status. This alignment streamlines charging decisions and elevates penalties for offenses involving fentanyl-related substances, regardless of whether a substance is explicitly listed as an analogue.
Effective date
Section 4 provides that the Act takes effect one day after enactment. This rapid operative date enables immediate impact on enforcement and regulatory strategies.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Law enforcement agencies (e.g., DEA, DOJ) benefit from a clearer, broader statutory basis to pursue fentanyl-related substance cases and to interdict evolving analogues.
- Public health and harm reduction programs gain a policy tool for preventing overdose deaths by reducing the availability of fentanyl-related substances through stricter scheduling.
- Prosecutors and courts benefit from a unified framework that simplifies charging decisions and aligns penalties with the intended severity of fentanyl-related substance offenses.
- Customs and border protection agencies gain a clearer authority to regulate import/export of fentanyl-related substances, closing importation channels.
- Regulated chemical suppliers and legitimate researchers operating under compliance programs benefit from explicit guidance that reduces ambiguity in how substances are controlled.
Who Bears the Cost
- Chemical manufacturers, distributors, and importers face heightened compliance burdens, recordkeeping, licensing, and potential liability for shipments containing fentanyl-related substances.
- State and local law enforcement agencies may need to allocate resources for training and enforcement related to expanded scheduling and new penalties.
- Healthcare and hospital systems could experience indirect cost pressures from enforcement actions and the need to adjust compliance protocols in laboratories and medical research settings.
- Courts and public defenders may experience greater caseloads and require resources to manage increased prosecutions under the new schedule and analogue-based penalties.
Key Issues
The Core Tension
The central dilemma is whether a broad, structurally driven definition that captures evolving fentanyl-related substances can be simultaneously protective of public health and workable for legitimate scientific and medical activity without creating excessive ambiguity or enforcement risk.
The bill’s broad definition of fentanyl-related substances aims to close loopholes but creates enforcement challenges, including the risk of over-criminalizing substances that may have legitimate research or medical applications. Without clear exemptions or guidance for legitimate laboratory use, researchers and regulated entities could face increased compliance costs and potential legal exposure for novel compounds that fall within the defined modification pathways.
The rapid enactment date could pressure agencies to build out new compliance, licensing, and enforcement protocols before the legal framework for these substances is fully operationally tested. The design thus hinges on the capacity of agencies to interpret the five modification pathways and to distinguish prohibited fentanyl-related substances from permissible research materials in real time.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.